Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CLP-290 是一种神经特异性 K+-Cl−共转运体 KCC2的口服激活剂,在多种神经和精神疾病方面具有研究潜力。CLP290 能显著降低 STZ 大鼠的血液中 AVP 和血糖水平。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 698 | 现货 | ||
10 mg | ¥ 1,259 | 现货 | ||
25 mg | ¥ 2,161 | 现货 | ||
50 mg | ¥ 3,471 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 614 | 现货 |
产品描述 | CLP290 is an activator of the neuron-specific K+-Cl cotransporter KCC2 and displays potential for the treatment of a wide range of neurological and psychiatric indications. |
体内活性 | In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons.?Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior. |
动物实验 | Morphine sulfate (50 mg/ml) was diluted in saline sterile solution immediately before injection.?Morphine or saline were subcutaneously injected twice a day (10 mg/kg;?9 a.m. 6 p.m.) in na?ve adult rats.?The KCC2 enhancer CLP257 and its carbamate pro-drug CLP290 were freshly diluted in 20% 2-hydroxypropyl-β-cyclodextrin (HPCD) prior injection.?CLP257 or vehicle were delivered intraperitoneally after 7 8 days of morphine or saline, as described (100 mg/kg).?CLP290 or vehicle were delivered orally by gavage twice a day for the whole duration of the morphine/saline treatment (100 mg/kg). |
别名 | CLP-290 |
分子量 | 404.46 |
分子式 | C19H21FN4O3S |
CAS No. | 1181083-81-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 12 mg/mL (29.67 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4724 mL | 12.3622 mL | 24.7243 mL | 61.8108 mL |
5 mM | 0.4945 mL | 2.4724 mL | 4.9449 mL | 12.3622 mL | |
10 mM | 0.2472 mL | 1.2362 mL | 2.4724 mL | 6.1811 mL | |
20 mM | 0.1236 mL | 0.6181 mL | 1.2362 mL | 3.0905 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CLP290 1181083-81-7 Membrane transporter/Ion channel Potassium Channel inhibit Inhibitor CLP-290 CLP 290 KcsA inhibitor